It wasn't until Tarceva extended the lives of patients with non-small cell lung cancer that it became clear that OSI and Genentech actually did have a potential blockbuster on their hands.
FORBES: OSI Chief Explains $935 Million Eyetech Buy
应用推荐
模块上移
模块下移
不移动